RNA integrity testing is a critical quality control step for clinical samples used in transcriptomics, molecular diagnostics, and precision medicine. This comprehensive guide covers the key integrity metrics—RIN, DV200, and rRNA ratios—the major clinical sample types, validated detection methods, and practical guidance for ensuring reliable downstream analytical results.
Technical Overview
RNA integrity refers to the degree to which RNA molecules remain structurally intact and undegraded from the moment of sample collection through extraction and analysis. Because RNA is inherently unstable and vulnerable to degradation by ubiquitous ribonucleases (RNases), assessing integrity is one of the most important quality control steps in any workflow involving clinical specimens. Poor RNA quality can introduce systematic bias, reduce sequencing depth, skew gene expression quantification, and ultimately invalidate experimental or diagnostic conclusions.
In clinical sample RNA integrity testing, total RNA is evaluated using several complementary parameters, including the RNA Integrity Number (RIN), DV200 score, 28S/18S ribosomal RNA ratio, concentration, and purity. These metrics are typically generated through microfluidic capillary electrophoresis platforms, which produce a digital electropherogram showing the size distribution of RNA fragments. The resulting profile allows laboratories to objectively classify samples as suitable or unsuitable for specific downstream applications such as RNA sequencing (RNA-seq), quantitative RT-PCR, microarray hybridization, or fusion gene testing.
RIN is the most widely adopted integrity metric and is expressed on a scale from 1 to 10, where 10 represents completely intact RNA and 1 represents highly degraded RNA. For formalin-fixed paraffin-embedded (FFPE) tissue, where chemical modification often prevents reliable RIN calculation, DV200—the percentage of RNA fragments longer than 200 nucleotides—is the recommended alternative standard established by international sequencing guidelines.
Testing Samples
Fresh Frozen Tissue
Surgically resected or biopsied tissue snap-frozen in liquid nitrogen represents the gold standard for RNA preservation. Samples are typically stored at -80°C until extraction. Rapid freezing within 30 minutes of devascularization is essential, as warm ischemia time directly correlates with RNA degradation. These specimens usually yield high RIN values above 7 when handled correctly.
FFPE Tissue
Formalin-fixed paraffin-embedded tissue is the most abundant archival clinical material in pathology departments worldwide. Although formalin fixation cross-links and fragments nucleic acids, properly fixed and stored FFPE blocks can still yield RNA suitable for targeted applications. DV200 assessment is the preferred integrity metric for these samples, with values above 30% generally acceptable for RNA-seq library preparation using FFPE-compatible protocols.
Whole Blood and Buffy Coat
Blood collected into dedicated RNA stabilization tubes, such as PAXgene Blood RNA Tubes, preserves cellular RNA for gene expression analysis at room temperature for extended periods. Buffy coat fractions separated from EDTA-anticoagulated blood are also commonly tested. Globin mRNA contamination is a characteristic consideration for blood-derived RNA and should be evaluated alongside integrity metrics.
Plasma and Serum (Cell-Free RNA)
Circulating and extracellular RNA in plasma and serum, including exosomal and microRNA populations, is inherently fragmented and cannot be assessed with conventional RIN. Integrity evaluation for these samples focuses on fragment size distribution and the presence of small RNA fractions rather than rRNA peaks.
Other Clinical Specimens
Additional sample types routinely submitted for RNA integrity testing include fine needle aspiration cell pellets, buccal and nasopharyngeal swabs, urine sediments, cerebrospinal fluid cells, bone marrow aspirates, and cultured primary cells derived from patient material.
Testing Items
A comprehensive RNA quality assessment for clinical samples typically includes the following measurable parameters:
- RNA Integrity Number (RIN): Algorithm-derived score from 1 to 10 reflecting overall RNA degradation status, based on the full electrophoretic profile including 18S and 28S rRNA peak heights and the inter-peak region.
- DV200: The percentage of RNA fragments exceeding 200 nucleotides in length, the recommended integrity metric for FFPE and other degraded samples per FDA and sequencing consortium guidelines.
- 28S/18S rRNA Ratio: A legacy metric where intact eukaryotic RNA ideally shows a ratio near 2.0; largely superseded by RIN but still reported for reference.
- RNA Concentration: Quantified in ng/µL using fluorometric methods such as Qubit RNA HS assay, which is more accurate than spectrophotometry at low concentrations.
- Purity Ratios: A260/A280 (target 1.8–2.1) indicating protein contamination, and A260/A230 (target 1.8–2.2) indicating organic solvent, salt, or phenol carryover.
- Fragment Size Distribution: Full electropherogram profile revealing degradation patterns, genomic DNA contamination, and small RNA content.
Testing Methods
Microfluidic Capillary Electrophoresis
Platforms such as the Agilent 2100 Bioanalyzer, Agilent TapeStation, and AATI Fragment Analyzer are the industry standards for RNA integrity assessment. Nanoliter-scale samples are separated through microfabricated channels, and fluorescent intercalating dyes generate real-time electropherograms. Dedicated assays distinguish total RNA (RIN), eukaryotic mRNA, and small RNA samples. These systems require minimal input, typically 1–5 µL of extract, and deliver automated RIN or RQN (RNA Quality Number) calls with high reproducibility.
Agarose Gel Electrophoresis
Denaturing agarose gel electrophoresis remains a low-cost qualitative option. Intact RNA displays two sharp bands corresponding to 28S and 18S rRNA in an approximately 2:1 intensity ratio, while degraded RNA appears as a smeared ladder of low-molecular-weight fragments. Although simple, this method is semi-quantitative, consumes larger sample volumes, and cannot generate a standardized RIN value.
Spectrophotometry and Fluorometry
NanoDrop-type spectrophotometers provide rapid concentration estimates and purity ratios but cannot assess integrity. Fluorometric assays using RNA-specific dyes (Qubit, RiboGreen) provide accurate quantification down to picogram levels and are used alongside electrophoretic methods to complete the quality profile.
RT-qPCR-Based Functional Assays
Functional integrity can be evaluated by amplifying housekeeping gene targets at the 3' and 5' ends of the same transcript. An elevated 3'/5' delta-Ct indicates degradation-driven bias. This approach directly measures amplifiability, which is often the most relevant predictor of performance in PCR-based clinical assays.
Applications
RNA integrity testing underpins quality assurance across a wide range of clinical and translational applications:
- RNA Sequencing (RNA-seq): Pre-library quality control ensuring that RIN or DV200 values meet protocol thresholds, preventing batch effects and biased transcript quantification in bulk and single-cell workflows.
- Quantitative RT-PCR and ddPCR: Verifying template suitability for gene expression panels, viral RNA detection, and minimal residual disease monitoring.
- Fusion Gene Diagnostics: Confirming RNA quality before testing for ALK, ROS1, NTRK, and RET fusions in lung cancer, sarcoma, and other malignancies using anchored multiplex PCR or targeted RNA panels.
- Gene Expression Microarrays: Screening specimens before hybridization, as degraded RNA compromises probe binding and signal uniformity.
- Biomarker Discovery and Biobanking: Establishing objective acceptance criteria for specimens entering research repositories and multi-center clinical trials.
- Liquid Biopsy Research: Characterizing cell-free and extracellular RNA fractions for non-invasive disease monitoring studies.
FAQ
Q: What RIN value is considered acceptable for RNA sequencing?
A: For standard bulk RNA-seq, a RIN of 7 or higher is generally recommended, with RIN ≥ 8 being ideal. Many modern low-input and degradation-tolerant library kits can accommodate RIN values down to 4–6, provided the protocol is validated for partially degraded input and additional cleanup steps are employed.
Q: Why is DV200 preferred over RIN for FFPE samples?
A: Formalin cross-linking and fragmentation alter the electropherogram in ways that distort RIN calculation, often producing misleadingly low scores even when RNA remains amplifiable. DV200 directly measures the fraction of fragments above 200 nucleotides, which correlates better with library construction success. A DV200 above 30% is commonly required for FFPE RNA-seq, though kits optimized for degraded material can tolerate lower values.
Q: How much sample is required for RNA integrity testing?
A: Microfluidic platforms typically require only 1–2 µL of RNA extract with a minimum concentration of 250 pg/µL for high-sensitivity chips. Because consumption is negligible, integrity testing can be integrated into routine workflows without compromising the material needed for downstream analysis.
Q: Can degraded clinical RNA still be used?
A: Yes, depending on the application. qRT-PCR assays using short amplicons (60–120 bp) tolerate substantial degradation. Exome-capture-based RNA-seq and 3'-end counting methods are also robust to moderate degradation. Whole-transcript or long-fragment applications, however, require high-integrity RNA and cannot be reliably performed on degraded specimens.
Q: How should clinical samples be handled to preserve RNA integrity?
A: Minimize warm ischemia time, stabilize tissue immediately by snap-freezing or immersion in RNA stabilization reagents, use RNase-free technique throughout processing, store frozen specimens at -80°C without freeze-thaw cycles, and transport blood in dedicated RNA stabilization tubes. Chain-of-custody documentation of processing times strengthens the interpretability of integrity results.